The 2025-2030 World Outlook for Neuroendocrine Tumor Treatments - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for Neuroendocrine Tumor Treatments

Subjects

Out of stock

Price data checked 6 days ago

View at Amazon

One email. No newsletter. No nudges.

Gone for 272 days. Could come back at any time — we're watching for you.

Out of stock 272 days · last price £790 · longest previous gap was 1 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 397 days · 397 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 397 days • 1 price levels

Days at Price

Price Analysis

Most common price: £790 (397 days, 100.0%)

Price range: £790 - £790

Price levels: 1 different prices over 397 days

Description

This study covers the world outlook for neuroendocrine tumor treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of neuroendocrine tumor treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Advanced Accelerator Applications, Amgen, AVEO Oncology, Boehringer Ingelheim International, Bristol-Myers Squibb, Dauntless Pharmaceuticals, Eli Lilly, Exelixis, F. Hoffmann-La Roche, Hutchison MediPharma, Ipsen Pharma, Novartis, Pfizer, Progenics Pharmaceuticals, Sanofi, Tarveda Therapeutics, and Teva Pharmaceuticals Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZMVDGN9
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 06 May 2024

The 2025-2030 World Outlook for Neuroendocrine Tumor Treatments

Gone for 272 days. Could come back at any time — we're watching for you.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in China

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in the United States

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments in India

The 2023-2028 Outlook for Neuroendocrine Tumor Treatments for US Zip Codes

Neuroendocrine Tumors: Surgical Evaluation and Management

Neuroendocrine Tumours: Diagnosis and Management

Neuroendocrine Tumors (Current Clinical Oncology)

The Spectrum of Neuroendocrine Neoplasia: A Practical Approach to Diagnosis, Classification and Therapy

Neuroendocrine Neoplasia Management: New Approaches for Diagnosis and Treatment

Neuroendocrine Neoplasms, An Issue of PET Clinics: Volume 18-2 (The Clinics: Radiology, Volume 18-2)

Springer - Abdominal Neuroendocrine Tumors (Updates in Surgery)

Humana Neuroendocrine Tumors - Current Clinical Oncology

The 2025-2030 World Outlook for Enteral Nutrition

The 2023-2028 Outlook for Head and Neck Oncology Nutrition in China

Neuroendocrine Tumours: Diagnosis and Management

Neuronal and Glioneuronal Tumors of the Central Nervous System (Neurology - Laboratory and Clinical Research Developments)

Atlas of Thyroid and Neuroendocrine Tumor Markers

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in the United States

The 2023-2028 World Outlook for Enteral Nutrition

Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in India

The 2021-2026 World Outlook for Non-Hodgkin Lymphoma (NHL) Therapeutics

The 2016-2021 World Outlook for Non-Small Cell Lung Cancer Therapeutics

The 2025-2030 World Outlook for Nondestructive Test Equipment